title: Hyperphosphatemia: a serious limiting factor preventing the possible benefit from intravenous calcitriol therapy.
authors.forename: N
authors.initials: N
authors.lastname: Arik
authors.forename: T
authors.initials: T
authors.lastname: Başoglu
authors.forename: C
authors.initials: C
authors.lastname: Sungur
authors.forename: B
authors.initials: B
authors.lastname: Adam
authors.forename: A
authors.initials: A
authors.lastname: Bedir
authors.forename: T
authors.initials: T
authors.lastname: Kandemir
authors.forename: C
authors.initials: C
authors.lastname: Coşkun
authors.forename: I
authors.initials: I
authors.lastname: Bernay
mesh_terms: D015502:Absorptiometry, Photon; D000469:Alkaline Phosphatase / Q000097:blood; D015519:Bone Density; D002117:Calcitriol / Q000008:administration & dosage / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy* / Q000209:etiology*; D007275:Injections, Intravenous; D010710:Phosphates / Q000097:blood*; D006435:Renal Dialysis / Q000009:adverse effects; D014511:Uremia / Q000628:therapy*
chemical_list: D010710:Phosphates; D000469:Alkaline Phosphatase; D002117:Calcitriol; D002118:Calcium